User login
Key clinical point: The albumin-bilirubin (ALBI) grade and alpha-fetoprotein (AFP) level of HCC patients at the start of regorafenib therapy was an independent predictor of disease control, progression-free survival after regorafenib therapy, and overall survival for both regorafenib and sorafenib-regorafenib sequential therapy.
Major finding: HCC patients with ALBI grade 2 and AFP level of 20 ng/mL or higher had worse rates of both progression-free survival for regorafenib alone (hazard ratio 3.088) and of overall survival for both regorafenib (HR 3.783) and sorafenib-regorafenib sequential therapy (HR 4.603) compared to those with ALBI grade one and lower AFP levels.
Study details: The data come from 88 adults with unresectable hepatocellular carcinoma who were treated with sorafenib-regorafenib sequential therapy.
Disclosures: The study received no outside funding. One study coauthor disclosed serving as an advisory committee member for AbbVie, Bristol-Myers Squibb, Gilead, and Roche. The lead author and other researchers had no financial conflicts to disclose.
Source: Wang H-W et al. Cancers (Basel). 2021 Jul 26. doi: 10.3390/cancers13153758.
Key clinical point: The albumin-bilirubin (ALBI) grade and alpha-fetoprotein (AFP) level of HCC patients at the start of regorafenib therapy was an independent predictor of disease control, progression-free survival after regorafenib therapy, and overall survival for both regorafenib and sorafenib-regorafenib sequential therapy.
Major finding: HCC patients with ALBI grade 2 and AFP level of 20 ng/mL or higher had worse rates of both progression-free survival for regorafenib alone (hazard ratio 3.088) and of overall survival for both regorafenib (HR 3.783) and sorafenib-regorafenib sequential therapy (HR 4.603) compared to those with ALBI grade one and lower AFP levels.
Study details: The data come from 88 adults with unresectable hepatocellular carcinoma who were treated with sorafenib-regorafenib sequential therapy.
Disclosures: The study received no outside funding. One study coauthor disclosed serving as an advisory committee member for AbbVie, Bristol-Myers Squibb, Gilead, and Roche. The lead author and other researchers had no financial conflicts to disclose.
Source: Wang H-W et al. Cancers (Basel). 2021 Jul 26. doi: 10.3390/cancers13153758.
Key clinical point: The albumin-bilirubin (ALBI) grade and alpha-fetoprotein (AFP) level of HCC patients at the start of regorafenib therapy was an independent predictor of disease control, progression-free survival after regorafenib therapy, and overall survival for both regorafenib and sorafenib-regorafenib sequential therapy.
Major finding: HCC patients with ALBI grade 2 and AFP level of 20 ng/mL or higher had worse rates of both progression-free survival for regorafenib alone (hazard ratio 3.088) and of overall survival for both regorafenib (HR 3.783) and sorafenib-regorafenib sequential therapy (HR 4.603) compared to those with ALBI grade one and lower AFP levels.
Study details: The data come from 88 adults with unresectable hepatocellular carcinoma who were treated with sorafenib-regorafenib sequential therapy.
Disclosures: The study received no outside funding. One study coauthor disclosed serving as an advisory committee member for AbbVie, Bristol-Myers Squibb, Gilead, and Roche. The lead author and other researchers had no financial conflicts to disclose.
Source: Wang H-W et al. Cancers (Basel). 2021 Jul 26. doi: 10.3390/cancers13153758.